Clinical features and outcome of HIV/SARS‐CoV‐2 coinfected patients in The Bronx, New York city

Suwanwongse, Kulachanya; Shabarek, Nehad

doi:10.1002/jmv.26077

Cited by 71 publications

(99 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Härter's cohort [26] has a similar mean age but showed higher severity, hospitalization, admission to ICU and mortality rates. However, differences are more difficult to assess with a smaller sample and in the absence of data related to subject comorbidities; the same limitations were found when comparing with the Wuhan [27] and New York [28] , [29] cohorts, both with a significantly higher median age. Finally, we found several similarities in our data with a recent systematic review [30] ; then, we suspect that the differences observed between the different cohorts are probably not significant.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in people living with HIV: A multicenter case-series study

Cabello¹,

Zamarro²,

Nistal³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 in people living with HIV: A multicenter case-series study

Cabello¹,

Zamarro²,

Nistal³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Several studies have suggested no increased risk of COVID-19 disease among those stably engaged in HIV care. [9][10][11][12][13][14] Furthermore, COVID-19 physical distancing recommendations may also decrease sexual and drug injection risk behaviour, thus reducing the risk of HIV transmission. 6 However, if hospitals and clinics reach their capacity, disadvantaged populations such as PWID may experience even greater barriers to medical care for COVID-19.…”

Section: Introductionmentioning

confidence: 99%

The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities

Zang

Krebs

Chen

et al. 2020

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Widespread viral and serological testing for SARS-CoV-2 may present a unique opportunity to also test for HIV infection. We estimated the potential impact of adding linked, opt-out HIV testing alongside SARS-CoV-2 testing on HIV incidence and the cost-effectiveness of this strategy in six US cities. Methods Using a previously-calibrated dynamic HIV transmission model, we constructed three sets of scenarios for each city: (1) sustained current levels of HIV-related treatment and prevention services (status quo); (2) temporary disruptions in health services and changes in sexual and injection risk behaviours at discrete levels between 0%-50%; and (3) linked HIV and SARS-CoV-2 testing offered to 10%-90% of the adult population in addition to scenario (2). We estimated cumulative HIV infections between 2020-2025 and incremental cost-effectiveness ratios of linked HIV testing over 20 years. Results In the absence of linked, opt-out HIV testing, we estimated a total of 16.5% decrease in HIV infections between 2020-2025 in the best-case scenario (50% reduction in risk behaviours and no service disruptions), and 9.0% increase in the worst-case scenario (no behavioural change and 50% reduction in service access). We estimated that HIV testing (offered at 10%-90% levels) could avert a total of 576-7,225 (1.6%-17.2%) new infections. The intervention would require an initial investment of $20.6M-$220.7M across cities; however, the intervention would ultimately result in savings in health care costs in each city. Conclusions A campaign in which HIV testing is linked with SARS-CoV-2 testing could substantially reduce HIV incidence and reduce direct and indirect health care costs attributable to HIV.

show abstract

“…For PLHIV with COVID-19, information about disease severity and patient outcomes is contradictory and several reports have shown that the mortality and severity of COVID-19 in PLHIV were not increased while other studies report worse evolution in patients with both infections. It is important to mention that most of these studies have reported several methodological limitations, especially the non-evaluation of residual confounders [54][55][56][57][58]. In PLHIV it is important to consider the presence of pulmonary fungal coinfections, especially due to the similarity in chest tomographic patterns.…”

Section: Discussionmentioning

confidence: 99%

Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV—A Case Report from Argentina and Literature Review

Messina

Marín

Cáceres

et al. 2020

JoF

View full text Add to dashboard Cite

The disease caused by the new SARS-CoV-2, known as Coronavirus disease 2019 (COVID-19), was first identified in China in December 2019 and rapidly spread around the world. Coinfections with fungal pathogens in patients with COVID-19 add challenges to patient care. We conducted a literature review on fungal coinfections in patients with COVID-19. We describe a report of a patient with disseminated histoplasmosis who was likely infected with SARS-CoV-2 and experienced COVID-19 during hospital care in Buenos Aires, Argentina. This patient presented with advanced HIV disease, a well-known factor for disseminated histoplasmosis; on the other hand, we suspected that COVID-19 was acquired during hospitalization but there is not enough evidence to support this hypothesis. Clinical correlation and the use of specific Histoplasma and COVID-19 rapid diagnostics assays were key to the timely diagnosis of both infections, permitting appropriate treatment and patient care.

show abstract

Clinical features and outcome of HIV/SARS‐CoV‐2 coinfected patients in The Bronx, New York city

Cited by 71 publications

References 7 publications

COVID-19 in people living with HIV: A multicenter case-series study

COVID-19 in people living with HIV: A multicenter case-series study

The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities

Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV—A Case Report from Argentina and Literature Review

Contact Info

Product

Resources

About